MILNER THERAPEUTICS CONSORTIUM
The Consortium has been active since June 2015 and is based on a research agreement signed by three academic centres in Cambridge and seven pharmaceutical companies: the University of Cambridge, the Sanger Institute and the Barbaham Institute (academic centres) and Astex, AstraZeneca, GlaxoSmithKline, Shionogi, Pfizer, Elysium and Johnson and Johnson. The agreement is designed to facilitate the speedy exchange of reagents and information and underpin research collaborations leading to publications.
The Consortium will provide researchers with the potential to access novel therapeutic agents (including small molecules and antibodies) across the entire portfolio of drugs being developed by each of the companies, in order to investigate their mechanism, efficacy and potential. Each industry partner within the Therapeutics Consortium has set aside funds for collaborative research projects between the Consortium members, which will be open to any therapeutic area and are expected to lead to joint publications. For information on current projects click here. For information on company areas of interest see the table below. The terms of the Consortium allow for fast and easy access to agents and information. The academic/industry interactions and match-making are facilitated by the Executive Manager. If you are interested in joining the Consortium please contact email@example.com.
For information on a company’s areas of interest click on their logo.
A flexible approach to collaboration
The Milner Therapeutics Consortium companies offer a wide range of collaborative opportunities to academic scientists which balance the needs of the company, the individual scientists involved and the project undertaken. These include advising on nascent drug development ideas, sabbaticals where academic scientists can spend time in industry and access to industry resource, equipment, compounds and funding. We aim to develop strong collaborations that play to each partner’s strengths.
The therapeutic areas of interest that Consortium companies have prioritised for collaboration are listed in the table above. More detail is provided in the individual pages for each company. Click on the company logo to see detail for AstraZeneca, Astex, GlaxoSmithKline or Shionogi. All companies are interested generally in technological innovation and new ideas in chemistry, mathematics and engineering that may span therapeutic areas.
Compound libraries are available
Compound banks from the companies are available for research and access to these is facilitated for scientists at the University of Cambridge, Sanger Institute and Babraham Institute through the Consortium agreement. Compound sets are available to explore disease biology, for preclinical and clinical research and also to reposition drugs that have already been tested in the clinic.
Contact us to find out more.